By Turna Ray

The recent approval of Pfizer's non-small cell lung cancer treatment Xalkori along with a companion test developed by Abbott Molecular serves as the latest example of how drug and diagnostic developers can use pharmacogenomic strategies to speed up drug development.

Xalkori's approval as an orphan drug also represents the successful use of available regulatory incentives to develop a drug that meets the unmet needs of a small, genomically defined patient subpopulation.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

A study appearing in Cell suggests some metastatic castration-resistant prostate cancer patients could benefit from PARP inhibitor therapy.

NIH's Francis Collins writes that scientific advances are poised to help populations all over the world, but more scientists are needed to keep the momentum.

In Science this week: swapping yeast genes with human orthologs to study conservation of function, and more.

Hong Kong is using DNA phenotyping to shame litterers.